Neele Dellschaft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Neele Dellschaft has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Robin C. Spiller
Nottingham NIHR Biomedical Research Centre University of Nottingham Nottingham UK
10 shared publications - Caroline Louise Hoad
Sir Peter Mansfield Imaging Centre University of Nottingham Nottingham UK
7 shared publications - Penny A. Gowland
Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
7 shared publications - Luca Marciani
NIHR Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
5 shared publications - Alan Robert Smyth
School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, Northern Ireland, United Kingdom
4 shared publications - Amisha Modasia
Quadram Institute Bioscience Norwich UK
4 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Letter: Timing Matters—Interpreting Colonic Gas Reduction With Gel‐Forming Fibres. Authors' Reply
- 21 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessLetter: Timing Matters—Interpreting Colonic Gas Reduction With Gel‐Forming Fibres. Authors' Reply
- 11 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (9) , 1197-1206
Clinical Trial: Randomised Placebo‐Controlled Trial of Methylcellulose and Psyllium Gels on Inulin‐Induced Colonic Gas
Background: People with irritable bowel syndrome (IBS) often restrict their intake of FODMAPs because of associated gas and abdominal discomfort. Psyllium, a gel‐forming fibre, reduces colonic gas after inulin ingestion. Objective: We aimed to determine whether methylcellulose, a low‐cost, non‐fermentable gelling agent, widely used in food manufacture, could be formulated to match psyllium's physical properties and similarly moderate colonic fermentation of inulin. Methods: 3‐way randomised cross‐over study giving 15 g inulin with 15 g methylcellulose, psyllium or maltodextrin (placebo) in 22 healthy volunteers. Participants underwent hourly MRI scans for 6 h and serial breath hydrogen measurements for 24 h when a final MRI scan was performed. Results: Methylcellulose and psyllium gels did not significantly alter AUC 0–360 min , however, they were associated with less colonic gas after the gels reached the colon (AUC 180–360 min , p = 0.02). The gels increased AUC 0–240 min of small bowel free water ( p < 0.0001 and 0.048, respectively), methylcellulose effect>psyllium ( p = 0.0005). Both increased colon chyme wateriness (T1AC, AUC 180–360 min , p < 0.0001) and volume of hydrated fibre in colon (AUC 180–360 min , p < 0.0001 and 0.0009, respectively). Both parameters were greater after methylcellulose than psyllium ( p = 0.01 and 0.02, respectively). 24 h measurements of breath hydrogen were not different between groups (AUC 0–24 h , p = 1.0) but were reduced by psyllium in the 0–6‐h period p = 0.008. Conclusions: Methylcellulose and psyllium reduce colonic gas produced by inulin after the gels reach the colon. Methylcellulose increases the water content of both the small and large bowel more than psyllium. This additional effect may allow improved tolerance of FODMAPs, particularly in IBS patients with constipation. Trial Registration: ClinicalTrials.gov identifier: NCT06291272
- 11 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (9) , 1197-1206
Clinical Trial: Randomised Placebo‐Controlled Trial of Methylcellulose and Psyllium Gels on Inulin‐Induced Colonic Gas
Background: People with irritable bowel syndrome (IBS) often restrict their intake of FODMAPs because of associated gas and abdominal discomfort. Psyllium, a gel‐forming fibre, reduces colonic gas after inulin ingestion. Objective: We aimed to determine whether methylcellulose, a low‐cost, non‐fermentable gelling agent, widely used in food manufacture, could be formulated to match psyllium's physical properties and similarly moderate colonic fermentation of inulin. Methods: 3‐way randomised cross‐over study giving 15 g inulin with 15 g methylcellulose, psyllium or maltodextrin (placebo) in 22 healthy volunteers. Participants underwent hourly MRI scans for 6 h and serial breath hydrogen measurements for 24 h when a final MRI scan was performed. Results: Methylcellulose and psyllium gels did not significantly alter AUC 0–360 min , however, they were associated with less colonic gas after the gels reached the colon (AUC 180–360 min , p = 0.02). The gels increased AUC 0–240 min of small bowel free water ( p < 0.0001 and 0.048, respectively), methylcellulose effect>psyllium ( p = 0.0005). Both increased colon chyme wateriness (T1AC, AUC 180–360 min , p < 0.0001) and volume of hydrated fibre in colon (AUC 180–360 min , p < 0.0001 and 0.0009, respectively). Both parameters were greater after methylcellulose than psyllium ( p = 0.01 and 0.02, respectively). 24 h measurements of breath hydrogen were not different between groups (AUC 0–24 h , p = 1.0) but were reduced by psyllium in the 0–6‐h period p = 0.008. Conclusions: Methylcellulose and psyllium reduce colonic gas produced by inulin after the gels reach the colon. Methylcellulose increases the water content of both the small and large bowel more than psyllium. This additional effect may allow improved tolerance of FODMAPs, particularly in IBS patients with constipation. Trial Registration: ClinicalTrials.gov identifier: NCT06291272
- Open Access
Gel-forming fibres differentially modulate inulin fermentation: A comparison of psyllium and methylcellulose in in vitro colonic models
1. Fermentable fibres such as inulin can support metabolic health but may exacerbate gastrointestinal symptoms in individuals with irritable bowel syndrome (IBS) due to rapid fermentation and gas production. The gel-forming fibre psyllium improves IBS symptoms, although the underlying mechanisms remain unclear. We hypothesised that fibre gelation alters fermentation by modulating microbial access to substrates. To test this, we compared psyllium with methylcellulose, a chemically modified, gel-forming fibre, to determine the effects of gelation on inulin fermentation. Inulin alone or combined with psyllium or methylcellulose was fermented for 48 hrs in a colonic fermentation model inoculated with healthy human faeces. Gas production, metabolite profiles, microbial community composition and microbial localisation within fibre gels were assessed. Bioactivity of fermentation products was evaluated in STC-1 cells. Psyllium co-fermentation significantly accelerated fermentation and enhanced production of metabolites, while methylcellulose had minimal effects. Psyllium maintained higher diversity and enriched polysaccharide-degrading taxa including Bacteroides and Phoecaeicola species, which were strongly associated with metabolic activity. Bacterial penetration into the psyllium matrix was observed but not into methylcellulose. Fermentation products from psyllium but not methylcellulose stimulated GLP-1 and 5-HT secretion in STC-1 cells. These findings demonstrate that delayed-onset fermentable gel-forming fibres enhance microbial access to entrapped substrates, driving metabolic and hormonal responses.
Open AccessGel-forming fibres differentially modulate inulin fermentation: A comparison of psyllium and methylcellulose in in vitro colonic models
1. Fermentable fibres such as inulin can support metabolic health but may exacerbate gastrointestinal symptoms in individuals with irritable bowel syndrome (IBS) due to rapid fermentation and gas production. The gel-forming fibre psyllium improves IBS symptoms, although the underlying mechanisms remain unclear. We hypothesised that fibre gelation alters fermentation by modulating microbial access to substrates. To test this, we compared psyllium with methylcellulose, a chemically modified, gel-forming fibre, to determine the effects of gelation on inulin fermentation. Inulin alone or combined with psyllium or methylcellulose was fermented for 48 hrs in a colonic fermentation model inoculated with healthy human faeces. Gas production, metabolite profiles, microbial community composition and microbial localisation within fibre gels were assessed. Bioactivity of fermentation products was evaluated in STC-1 cells. Psyllium co-fermentation significantly accelerated fermentation and enhanced production of metabolites, while methylcellulose had minimal effects. Psyllium maintained higher diversity and enriched polysaccharide-degrading taxa including Bacteroides and Phoecaeicola species, which were strongly associated with metabolic activity. Bacterial penetration into the psyllium matrix was observed but not into methylcellulose. Fermentation products from psyllium but not methylcellulose stimulated GLP-1 and 5-HT secretion in STC-1 cells. These findings demonstrate that delayed-onset fermentable gel-forming fibres enhance microbial access to entrapped substrates, driving metabolic and hormonal responses.
- 10 January 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (4) , e14999
Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function
Background: The human colon receives 2 L of fluid daily. Small changes in the efficacy of absorption can lead to altered stool consistency with diarrhea or constipation. Drugs and formulations can also alter colonic water, which can be assessed using the magnetic resonance imaging (MRI) longitudinal relaxation time constant, T1. We explore the use of regional T1 assessment in evaluating disorders of colonic function.Methods: Individual participant data analysis of data from 12 studies from a single center of patients with constipation, irritable bowel syndrome with diarrhea (IBS‐D), and healthy volunteers (HV). T1 was quantified by measuring the signal from the tissue at different times after a pulse which inverts the magnetization.Key Results: When diarrhea was induced by a macrogol laxative T1 in the ascending colon, T1AC was negatively correlated with stool bacterial content, r2 = 0.78, p < 0.001. T1AC was increased by another laxative, rhubarb. Patients with IBS‐D had elevated fasting T1AC (0.78 ± 0.28 s, N = 67) compared to HV (0.62 ± 0.21 s, N = 92) while those with constipation lay within the normal range (HV 10–90th centiles 0.33–0.91 s). Fasting T1AC in IBS‐D was reduced by mesalazine treatment. T1 in the descending colon was consistently lower than T1AC, with a bigger reduction in patients with constipation than HV. Pre‐feeding dietary fiber (bran, nopal, and psyllium) was associated with fasting T1AC at or above the normal 90th centile.Conclusions and Inferences: T1 is an MRI parameter which could be used to monitor effectiveness of novel agents designed to alter colonic water content and stool consistency.
- 10 January 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (4) , e14999
Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function
Background: The human colon receives 2 L of fluid daily. Small changes in the efficacy of absorption can lead to altered stool consistency with diarrhea or constipation. Drugs and formulations can also alter colonic water, which can be assessed using the magnetic resonance imaging (MRI) longitudinal relaxation time constant, T1. We explore the use of regional T1 assessment in evaluating disorders of colonic function.Methods: Individual participant data analysis of data from 12 studies from a single center of patients with constipation, irritable bowel syndrome with diarrhea (IBS‐D), and healthy volunteers (HV). T1 was quantified by measuring the signal from the tissue at different times after a pulse which inverts the magnetization.Key Results: When diarrhea was induced by a macrogol laxative T1 in the ascending colon, T1AC was negatively correlated with stool bacterial content, r2 = 0.78, p < 0.001. T1AC was increased by another laxative, rhubarb. Patients with IBS‐D had elevated fasting T1AC (0.78 ± 0.28 s, N = 67) compared to HV (0.62 ± 0.21 s, N = 92) while those with constipation lay within the normal range (HV 10–90th centiles 0.33–0.91 s). Fasting T1AC in IBS‐D was reduced by mesalazine treatment. T1 in the descending colon was consistently lower than T1AC, with a bigger reduction in patients with constipation than HV. Pre‐feeding dietary fiber (bran, nopal, and psyllium) was associated with fasting T1AC at or above the normal 90th centile.Conclusions and Inferences: T1 is an MRI parameter which could be used to monitor effectiveness of novel agents designed to alter colonic water content and stool consistency.
- Open Access
- 16 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (5) , 1284-1291
Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo‐controlled Trial in Constipation
Bisacodyl is a widely used laxative that stimulates both motility and secretion. Our aim was to exploit the unique capabilities of MRI to define bisacodyl's mode of action. Two placebo‐controlled cross‐over trials were performed, one using a single dose of Bisacodyl 5 mg while the second dosed daily for 3 consecutive days. Serial MRI was performed every 75 minutes. Primary endpoint: ascending colon water content as assessed by T1AC AUC300–450 minutes. Secondary endpoints included: small bowel water content, whole gut transit time (WGTT), colonic volumes, stool frequency, and consistency using Bristol Stool Form Score (BSFS). Exploratory endpoints: changes in the serial segmental volumes were quantified from the number of “mass movements” defined as episodes when segmental volume change from the previous scan was > 20% of baseline volume. We also measure the time to defecate after dosing. After 3 days of bisacodyl, ascending colon water content (T1) was 62% greater than after placebo, mean difference T1 AUC300–450 minutes 50.2 (61.0) sec.min, 95% CI (9.2, 91.2), P = 0.02, while after a single dose difference was only 11% (P = 0.58). Both single and repeated doses shortened WGTT (P < 0.049) and time to defecate (P 0.01). Only repeated doses significantly increased small bowel water content (P < 0.03), the number of “mass movements” (P = 0.048), bowel frequency (P = 0.006), and BSFS (P = 0.03). Repeated, compared to single dosing of Bisacodyl, additionally increases small bowel and colon water content and increases the number of “mass movements” thereby increasing its laxative effect. MRI is a non‐invasive, patient‐acceptable technique for evaluating drugs which alter secretion and/or motility.
- 16 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (5) , 1284-1291
Open AccessMagnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo‐controlled Trial in Constipation
Bisacodyl is a widely used laxative that stimulates both motility and secretion. Our aim was to exploit the unique capabilities of MRI to define bisacodyl's mode of action. Two placebo‐controlled cross‐over trials were performed, one using a single dose of Bisacodyl 5 mg while the second dosed daily for 3 consecutive days. Serial MRI was performed every 75 minutes. Primary endpoint: ascending colon water content as assessed by T1AC AUC300–450 minutes. Secondary endpoints included: small bowel water content, whole gut transit time (WGTT), colonic volumes, stool frequency, and consistency using Bristol Stool Form Score (BSFS). Exploratory endpoints: changes in the serial segmental volumes were quantified from the number of “mass movements” defined as episodes when segmental volume change from the previous scan was > 20% of baseline volume. We also measure the time to defecate after dosing. After 3 days of bisacodyl, ascending colon water content (T1) was 62% greater than after placebo, mean difference T1 AUC300–450 minutes 50.2 (61.0) sec.min, 95% CI (9.2, 91.2), P = 0.02, while after a single dose difference was only 11% (P = 0.58). Both single and repeated doses shortened WGTT (P < 0.049) and time to defecate (P 0.01). Only repeated doses significantly increased small bowel water content (P < 0.03), the number of “mass movements” (P = 0.048), bowel frequency (P = 0.006), and BSFS (P = 0.03). Repeated, compared to single dosing of Bisacodyl, additionally increases small bowel and colon water content and increases the number of “mass movements” thereby increasing its laxative effect. MRI is a non‐invasive, patient‐acceptable technique for evaluating drugs which alter secretion and/or motility.
- Open Access
- 14 May 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 967-976
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
- 14 May 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 967-976
Open AccessImpact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
- Open Access
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
Background There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study, we investigated longitudinal Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on the gut microbiota, metabolomic functioning, and clinical outcomes in people with CF (pwCF). Study design Faecal samples from 20 pwCF were acquired before and then following 3, 6, and 17+ months of ETI therapy. Samples were subjected to microbiota sequencing and targeted metabolomics to profile and quantify short-chain fatty acid composition. Ten healthy matched controls were included for comparison. Clinical data, including markers of intestinal function were integrated to investigate relationships. Results Extended ETI therapy increased core microbiota diversity and composition, which translated to gradual shifts in whole microbiota composition towards that observed in healthy controls. Despite becoming more similar over time, CF microbiota and functional metabolite compositions remained significantly different to healthy controls. Antibiotic treatment for pulmonary infection significantly explained a relatively large degree of variation within the whole microbiota and rarer satellite taxa. Clinical outcomes were not significantly different following ETI. Conclusions A positive trajectory towards the microbiota observed in healthy controls was found. However, we posit that progression was predominately impeded by pulmonary antibiotics administration. We recommend future studies use integrated omics approaches within a combination of long-term longitudinal patient studies and model experimental systems. This will deepen our understanding of the impacts of CFTR modulator therapy and respiratory antibiotic interventions upon the gut microbiome and gastrointestinal pathophysiology in CF.
Open AccessImpact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
Background There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study, we investigated longitudinal Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on the gut microbiota, metabolomic functioning, and clinical outcomes in people with CF (pwCF). Study design Faecal samples from 20 pwCF were acquired before and then following 3, 6, and 17+ months of ETI therapy. Samples were subjected to microbiota sequencing and targeted metabolomics to profile and quantify short-chain fatty acid composition. Ten healthy matched controls were included for comparison. Clinical data, including markers of intestinal function were integrated to investigate relationships. Results Extended ETI therapy increased core microbiota diversity and composition, which translated to gradual shifts in whole microbiota composition towards that observed in healthy controls. Despite becoming more similar over time, CF microbiota and functional metabolite compositions remained significantly different to healthy controls. Antibiotic treatment for pulmonary infection significantly explained a relatively large degree of variation within the whole microbiota and rarer satellite taxa. Clinical outcomes were not significantly different following ETI. Conclusions A positive trajectory towards the microbiota observed in healthy controls was found. However, we posit that progression was predominately impeded by pulmonary antibiotics administration. We recommend future studies use integrated omics approaches within a combination of long-term longitudinal patient studies and model experimental systems. This will deepen our understanding of the impacts of CFTR modulator therapy and respiratory antibiotic interventions upon the gut microbiome and gastrointestinal pathophysiology in CF.
- 30 October 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (3) , 327-338
Small bowel water content assessed by MRI in health and disease: a collation of single‐centre studies
Summary: Background: New developments in MRI have allowed the non‐invasive, accurate measurement of the small bowel water content (SBWC).Aims: To collate studies measuring SBWC following ingestion of a range of foods in both health and disease to provide data for adequately powering future studies in this area.Methods: This collation brings together 29 studies including 954 participants (530 healthy, 54 diverticulosis, 255 IBS, 53 functional constipation, 12 cystic fibrosis, 15 Crohn's disease, 20 coeliac disease, 15 scleroderma) which have been carried out in a single centre using comparable study designs.Results: Fasting SBWC (mean 82 [SD 65] mL) shows high variability with a small decline with advancing age (healthy volunteers only; individual patient data). Fasting values are increased in untreated coeliac disease (202 [290] mL, P = 0.004). Post‐prandial SBWC shows less intra‐individual variability than fasting values in healthy volunteers. SBWC is increased by eating, most markedly by high fat meals but also by fibre, both viscous and particulate. Indigestible residue accumulates in late post‐prandial period but empties soon after ingestion of a high calorie meal which produces a significant drop (by 50 [52] mL) in healthy volunteers. The associated fall in SBWC is abnormal in people with cystic fibrosis (SBWC reduced by 10 [121] mL, P = 0.002) and in people with irritable bowel syndrome with diarrhoea (SBWC reduced by 17 [43] mL, P = 0.007).Conclusions: SBWC as assessed by MRI is a valuable biomarker indicating the balance of secretion and absorption in health and disease and the impact of treatments.
- 30 October 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (3) , 327-338
Small bowel water content assessed by MRI in health and disease: a collation of single‐centre studies
Summary: Background: New developments in MRI have allowed the non‐invasive, accurate measurement of the small bowel water content (SBWC).Aims: To collate studies measuring SBWC following ingestion of a range of foods in both health and disease to provide data for adequately powering future studies in this area.Methods: This collation brings together 29 studies including 954 participants (530 healthy, 54 diverticulosis, 255 IBS, 53 functional constipation, 12 cystic fibrosis, 15 Crohn's disease, 20 coeliac disease, 15 scleroderma) which have been carried out in a single centre using comparable study designs.Results: Fasting SBWC (mean 82 [SD 65] mL) shows high variability with a small decline with advancing age (healthy volunteers only; individual patient data). Fasting values are increased in untreated coeliac disease (202 [290] mL, P = 0.004). Post‐prandial SBWC shows less intra‐individual variability than fasting values in healthy volunteers. SBWC is increased by eating, most markedly by high fat meals but also by fibre, both viscous and particulate. Indigestible residue accumulates in late post‐prandial period but empties soon after ingestion of a high calorie meal which produces a significant drop (by 50 [52] mL) in healthy volunteers. The associated fall in SBWC is abnormal in people with cystic fibrosis (SBWC reduced by 10 [121] mL, P = 0.002) and in people with irritable bowel syndrome with diarrhoea (SBWC reduced by 17 [43] mL, P = 0.007).Conclusions: SBWC as assessed by MRI is a valuable biomarker indicating the balance of secretion and absorption in health and disease and the impact of treatments.
- 1 July 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (4) , 591-597
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging
- 1 July 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (4) , 591-597
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging